[A23-68] Dimethyl fumarate (relapsing remitting multiple sclerosis) –Benefit assessment according to §35a Social Code Book V
Last updated 16.10.2023
Project no.:
A23-68
Commission:
Commission awarded on 06.07.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Children and adolescents (≥ 13 to < 18 years) with relapsing remitting multiple sclerosis who have not yet received disease-modifying therapy, or children and adolescents pretreated with disease-modifying therapy whose disease is not highly active
Hint of non-quantifiable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://dx.doi.org/10.60584/A23-68